Novo Nordisk sues Pfizer over Exubera

Share this article:
Novo Nordisk has sued Pfizer claiming the new product Exubera violates patents on inhalable insulin. “We’re trying to protect our intellectual property,” Novo Nordisk general counsel Jim Shehan said in a CNNMoney.com report. “We’ve been a leader in diabetes for 80 years. For us to keep that leadership position it’s essential that our intellectual property rights are respected.” Shehan told the Web site Exubera violates five Novo Nordisk patents involving inhaled insulin and that the first of his company’s patents was filed in 1993. Novo Nordisk filed its suit on Tuesday in federal court in Manhattan, where Pfizer is based. Pfizer spokesman Bryant Haskins released the following statement in response to the lawsuit: “Pfizer has not had an opportunity to review the Novo Nordisk complaint, but we are confident in the innovation behind the development of this new medicine.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.